GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oxurion NV (XBRU:OXUR) » Definitions » ROE % Adjusted to Book Value

Oxurion NV (XBRU:OXUR) ROE % Adjusted to Book Value : 0.00% (As of Dec. 2023)


View and export this data going back to 2006. Start your Free Trial

What is Oxurion NV ROE % Adjusted to Book Value?

Oxurion NV's ROE % for the quarter that ended in Dec. 2023 was 0.00%. Oxurion NV's PB Ratio for the quarter that ended in Dec. 2023 was N/A. Oxurion NV's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 was N/A.


Oxurion NV ROE % Adjusted to Book Value Historical Data

The historical data trend for Oxurion NV's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oxurion NV ROE % Adjusted to Book Value Chart

Oxurion NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -30.79 -18.43 - - -

Oxurion NV Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Oxurion NV's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Oxurion NV's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oxurion NV's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oxurion NV's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Oxurion NV's ROE % Adjusted to Book Value falls into.



Oxurion NV ROE % Adjusted to Book Value Calculation

Oxurion NV's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

Oxurion NV's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Oxurion NV ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Oxurion NV's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Oxurion NV (XBRU:OXUR) Business Description

Industry
Traded in Other Exchanges
Address
Gaston Geenslaan 1, Leuven, BEL, B-3001
Oxurion NV is a clinical stage biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME). The Group's research and development facilities are located in Belgium .The Company is engaged in the development of drugs to treat back-of-the-eye diseases, more specifically, ophthalmologic pharmaceuticals to treat vascular retinal disorders, specifically DME.

Oxurion NV (XBRU:OXUR) Headlines

No Headlines